Data from three cohorts of patients with early stage pancreatic ductal adenocarcinoma (PDAC) indicate that a two-protein biomarker panel, consisting of plasma tissue factor pathway inhibitor (TFPI) and tenascin-C (TNC-FN-III-C), as measured in plasma samples using an ELISA improves the prognostic value of CA 19-9. This biomarker panel enabled accurate discrimination between patients with, and those without early stage PDAC, and was also effective in discriminating between patients with diabetes or pancreatitis and those with PDAC. These findings improve upon the prognostic effectiveness of CA 19-9, the previous gold-standard biomarker.
References
Balasenthil, S. et al. A plasma biomarker panel to identify surgically resectable early-stage pancreatic cancer. J. Natl. Cancer Inst. 109, djw341 (2017)
Rights and permissions
About this article
Cite this article
Sidaway, P. New biomarkers improve standard screening. Nat Rev Clin Oncol 14, 262 (2017). https://doi.org/10.1038/nrclinonc.2017.35
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.35
This article is cited by
-
Blockade of integrin α3 attenuates human pancreatic cancer via inhibition of EGFR signalling
Scientific Reports (2019)